厄贝沙坦片联合精蛋白生物合成人胰岛素注射液治疗老年2型糖尿病肾病的临床研究

发布时间：2018-12-16 04:08

【摘要】：目的观察厄贝沙坦片联合精蛋白生物合成人胰岛素注射液治疗老年2型糖尿病肾病患者的临床疗效及安全性。方法将100例老年2型糖尿病肾病患者随机分为对照组50例和试验组50例。对照组予以精蛋白生物合成人胰岛素0.25 U·kg~(-1)·d~(-1),bid,早餐和晚餐前皮下注射;试验组在对照组治疗的基础上,予以厄贝沙坦150 mg,qd,口服。2组患者均治疗3个月。比较2组患者的临床疗效、血尿素氮(BUN)、血清肌酸酐(SCr)、24 h尿白蛋白排泄率(24 h UAER),以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为94.00%(47/50例)和76.00%(38/50例),差异有统计学意义(P0.05)。治疗后,试验组和对照组的BUN分别为(6.84±0.56)和(7.67±0.70)mmol·L~(-1),SCr分别为(76.49±8.05)和(86.39±8.04)μmol·L~(-1),24 h UAER分别为(68.02±6.75)和(78.70±7.52)mg·24 h~(-1),差异均有统计学意义(均P0.05)。2组患者的药物不良反应以头痛、眩晕、心悸、咳嗽为主,且试验组和对照组的药物不良反应率分别为16.00%和22.00%,差异无统计学意义(P0.05)。结论厄贝沙坦片联合精蛋白生物合成人胰岛素注射液治疗老年2型糖尿病肾病的临床疗效确切,其能有效地改善患者的肾功能,且不增加药物不良反应的发生率。
[Abstract]:Objective to observe the clinical efficacy and safety of irbesartan tablets combined with protamine biosynthetic human insulin injection in the treatment of elderly patients with type 2 diabetic nephropathy. Methods 100 elderly patients with type 2 diabetic nephropathy were randomly divided into control group (n = 50) and experimental group (n = 50). The control group was subcutaneously injected with human insulin 0.25 U kg~ (-1) D1), bid, before breakfast and dinner. The experimental group was treated with irbesartan for 150 mg,qd, on the basis of control group. The patients in both groups were treated for 3 months. The clinical efficacy, urinary albumin excretion rate (24 h UAER),) and adverse drug reaction (ADR) of serum creatinine (SCr), (24 h UAER),) in serum urea nitrogen (BUN),) were compared between the two groups. Results after treatment, the total effective rates of the experimental group and the control group were 94.00% (47 / 50 cases) and 76.00% (38 / 50 cases), respectively. The difference was statistically significant (P0.05). After treatment, the BUN of the experimental group and the control group were (6.84 卤0.56) and (7.67 卤0.70) mmol L ~ (-1), SCr, respectively (76.49 卤8.05) and (86.39 卤8.04) 渭 mol L ~ (-1), respectively. 24 h UAER were (68.02 卤6.75) and (78.70 卤7.52) mg 24 h ~ (-1), respectively, the difference was statistically significant (P0.05). The adverse drug reactions of the two groups were headache, dizziness, palpitation and cough. The adverse drug reaction rates in the test group and the control group were 16.00% and 22.00%, respectively, with no significant difference (P0.05). Conclusion Irbesartan tablet combined with protamine biosynthetic human insulin injection is effective in the treatment of senile type 2 diabetic nephropathy. It can effectively improve the renal function of the patients without increasing the incidence of adverse drug reactions.
【作者单位】：杭州市第三人民医院肾内科;
【基金】：浙江省医药卫生计划基金资助项目(2011ZHA003)
【分类号】：R587.2;R692.9

【相似文献】